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Purpose of the study
The frequency and reasons for switching antiretrovirals
(ARVs) in patients on a fully suppressed cART regimen
(viral load [VL] <50copies/ml) is not well described, nor
is the effect of such a change on CD4 counts.
Methods
6713 patients from EuroSIDA on cART with a confirmed
VL<50 copies/ml were included; a regimen change was
defined as >1 ARV change (occurring on the same day)
for any reason whilst VL< 50 copies/ml. Baseline was
defined as the first VL<50 copies/ml on cART; Kaplan
Meier methods estimated the probability of ARV change
and Cox proportional hazards models, stratified by cen-
tre, identified factors associated with ARV change. Mixed
models were used to model the change in CD4 count
after the first ARV change.
Results
At baseline, the median CD4 was 414/mm
3 (IQR 272—
587). 1079 (16.1%) patients changed 1358 ARVs; 93
(8.6%) patients started an ARV they had previously
taken. 224 (77.0%) of those starting an NNRTI (n=291)
were previously naïve to NNRTIs, compared to 29 of
306 who started a PI or boosted-PI (9.5%). The inci-
dence of changing ARVs was 11.8 per 100 PYFU (95%
CI 11.1-12.5). At 1 year after baseline, 10.7% were esti-
mated to have changed >1 ARV (95% CI 9.8-11.5). The
most common reason for change was toxicity (n=521,
38.4%), followed by patient or physician choice (n=398,
29.3%). Table 1 shows the factors associated with chan-
ging ARVs.
After adjustment, changing ARVs was associated with
an additional annual increase in CD4 counts of 9.3/mm
3
per year (95% CI 5.7-12.9/mm
3) compared to not chan-
ging ARVs. The increase was similar in patients who
recycled ARVs compared to those starting an ARV to
which they were naive, according to type of new ARV
started (nucleoside, PI, boosted-PI or NNRTI), and
number of new ARVs started (0, 1 or >2, p>0.05 all).
Patients starting a new ARV class had higher increases
in CD4 counts compared to those who changed ARVs
but did not start a new class (8.0/mm
3; 95% CI 0.2-15.8/
mm
3, p=0.044), although there was no differences
between PI-containing or NNRTI-containing classes
(p=0.54).
Conclusions
Changing ARVs whilst virologically suppressed was due
to patient/physician choice or toxicity, increased in fre-
quency over time and was more common in patients
taking a single PI-regimen or in stavudine-containing
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Table 1
Multivariate
RH 95% CI P
Gender Female versus Male 1.29 1.09-1.53 0.0038
Risk group Heterosexual versus other 0.83 0.70-0.98 0.033
Basline Per year later 1.32 1.27-1.38 <0.0001
Nucleoside pair Zidovudine/lamivudine 1.00 - -
Didanosine/stavudine 1.94 1.49-2.53 <0.0001
Stavudine/lamivudine 1.81 1.50-2.17 <0.0001
Tenofovir plus 1 0.87 0.68-1.10 0.24
Abacavir plus 1 0.62 0.46-0.83 0.0012
Other not listed 1.06 0.80-1.40 0.68
Third drug Single PI 1.00 - -
Boosted PI 0.46 0.36-0.58 <0.0001
NNRTI 0.42 0.35-0.50 <0.0001
Triple nucleoside 0.23 0.16-0.35 <0.0001
HCV serostatus Positive versus negative/
unknown
0.80 0.67-0.96 0.017
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statistically significant boost to CD4 count levels, and
the increase in CD4 was higher in those who changed
to a new class of ARV.
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